Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.
Lebbé C, Italiano A, Houédé N, Awada A, Aftimos P, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Raymond E, Faivre S, Pages C, Gomez-Roca C, Schueler A, Goodstal S, Massimini G, Delord JP.
Lebbé C, et al. Among authors: schueler a.
Target Oncol. 2021 Jan;16(1):47-57. doi: 10.1007/s11523-020-00767-1.
Target Oncol. 2021.
PMID: 33211315
Clinical Trial.